The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index (IBB) is down 19% so far in 2016, …
In a research report released Monday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), with a …
Analysts are weighing in on the biopharmaceutical companies Cytori Therapeutics Inc (NASDAQ:CYTX) and Osiris Therapeutics, Inc. (NASDAQ:OSIR), as shares of both companies fell …
Maxim’s healthcare analyst Jason Kolbert reiterated coverage on the clinical-stage biopharmaceutical company Anavex Life Sciences Corp. (NASDAQ:AVXL) and cell therapy company Cytori Therapeutics Inc (NASDAQ:CYTX).
Analysts are weighing in on the clinical-stage biopharmaceutical company Anavex Life Sciences Corp. (NASDAQ:AVXL) and Israeli pharma company Oramed Pharmaceuticals, Inc.
In a research report released today, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), while introducing a new …
In a research note issued Friday, Maxim analyst Jason McCarthy reiterated a Hold rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), after the …
Maxim’s healthcare analyst Jason Kolbert weighted in today on the clinical-stage biopharmaceutical company Anavex Life Sciences Corp. (NASDAQ:AVXL) and stem cell research company StemCells Inc (NASDAQ:STEM).
Analysts are weighing in on pharmaceutical giants Gilead Sciences, Inc. (NASDA:GILD), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Abbott Laboratories (NYSE:ABT) with mixed ratings.
Maxim’s healthcare analysts are weighing in on the Boston drug company Keryx Biopharmaceuticals (NASDAQ:KERX) and cancer drug discovery company Kite Pharma Inc (NASDAQ:KITE), following recent announcements. Keryx Biopharmaceuticals In a …
